Compounds and methods for treating neoplasia

A compound of Formula (I)

• wherein:
• represents a single bond or double bond in the ring structure of Formula (I);
• One of R1 and R2 is H, and the other is —OR3;
• alkyl optionally substituted with hydroxyl or alkoxy;
• —C(O)—NH2;
• —C(O)—O-alkyl;
• —NHR8;
• alkynyl;
• or Wand R2 together with the carbon to which they are attached form C═O, C═C(R9)2, or CN—OR10;
• R3 is H;
• —NO2;
• carbonylalkyl;
• carbonylaryl;
• or aminoalkyl optionally substituted with one or more alkyl;
• A is CH(OR4), C═N—OR5, CH—CH═N—OR6, C═CH—CH═N—OR6, CH—CH═CH—R6, CH—SR7, or CH—S(O)R7;
• R4 is alkyl optionally substituted by a 4- to 6-membered heterocyclic ring, a 5 to 14-membered heteroaryl, amino(C1-C4)alkoxyl, (C1-C4)alkoxyl substituted by a 4- or 6-membered heterocyclic ring, or guanidinyl;
• aminoalkyl optionally substituted by one or more alkyl;
• or aminoacyl optionally substituted by alkyl;
• wherein said heterocyclic or heteroaryl ring is further optionally substituted by one or more alkyl
• R5 is aminoalkyl optionally substituted by one or more alkyl or acetyl;
• alkyl optionally substituted by guanidinyl, heteroaryl that is further optionally substituted by one or more alkyl or aminoalkyl optionally substituted by one or more alkyl, or a 4- to 6-membered heterocyclic ring that is further optionally substituted by one or more alkyl;
• or a 4- to 6-membered heterocyclic ring optionally substituted by one or more alkyl;
• R6 and R7, each independently, are aminoalkyl optionally substituted by one or more alkyl;
• R8 is H or formyl;
• R9, for each occurrence, is the same or different and is H or halogen;
• R10 is H or alkyl;
• and
• tautomers, stereoisomers, Z and E isomers, optical isomers, N-oxides, hydrates, polymorphs, pharmaceutically acceptable esters, salts, prodrugs and/or isotopic derivatives thereof.